Paul Talmo - Jan 1, 2022 Form 3 Insider Report for TELA Bio, Inc. (TELA)

Role: Chief Strategic Officer
Signature: /s/ Megan Smeykal, Attorney-in-fact
Stock symbol: TELA
Transactions as of: Jan 1, 2022
Transactions value $: $0
Form type: 3
Date filed: 1/7/2022, 03:25 PM
Next filing: Feb 25, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	TELA	Common Stock						30.5K	Jan 1, 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	TELA	Stock Option (Right to Buy)							Jan 1, 2022	Common Stock	4.05K	$5.93	Direct	F2
holding	TELA	Stock Option (Right to Buy)							Jan 1, 2022	Common Stock	10.1K	$5.93	Direct	F3
holding	TELA	Stock Option (Right to Buy)							Jan 1, 2022	Common Stock	10.1K	$5.93	Direct	F4
holding	TELA	Stock Option (Right to Buy							Jan 1, 2022	Common Stock	9.8K	$5.93	Direct	F5
holding	TELA	Stock Option (Right to Buy							Jan 1, 2022	Common Stock	70.9K	$13.00	Direct	F6
holding	TELA	Stock Option (Right to Buy							Jan 1, 2022	Common Stock	21.5K	$16.99	Direct	F7
holding	TELA	Warrants (Right to Buy)							Jan 1, 2022	Common Stock	204	$28.65	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Common stock includes 11,800 restricted stock units and 2,510 restricted stock units that will vest in four equal annual installments beginning on February 24, 2022 and March 31, 2022, respectively, each subject to the Reporting Person's continued service through the applicable vesting dates.
F2	The option vested 50% on February 24, 2017 and 12.5% on February 24, 2018, with the remaining 37.5% having vested in equal monthly installments on the last day of each of the 36 calendar months immediately following February 2018.
F3	The option vested immediately upon TELA Bio, Inc. (the "Company") achieving cumulative net sales exceeding $10.0 million.
F4	The option vested immediately upon the Company achieving cumulative net sales exceeding $30.0 million.
F5	The option vested 25% on February 28, 2019, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service through the applicable vesting dates.
F6	The option vested 25% on November 7, 2020, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service through the applicable vesting dates.
F7	The option vests 25% on February 24, 2022, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service through the applicable vesting dates.